<DOC>
	<DOCNO>NCT01521338</DOCNO>
	<brief_summary>The goal research study collect blood urine sample people either R117H type CF non-G551D gating type CF keep future research.We also use collect blood measure number neutrophil .</brief_summary>
	<brief_title>G551D Observational Study- Expanded Additional Genotypes Extended Long Therm Follow ( GOAL-e2 )</brief_title>
	<detailed_description>- Blood Collection : Blood collect keep research future measure number blood cell call neutrophil . A small needle use collect blood vein arm . About 7-9 teaspoon blood would collect . - Sweat Collection : Your sweat collect special sweat collection machine test amount salt sweat . - Spirometry : You ask take test measure well lung work . You ask take deep breath blow mouthpiece hard possible long possible . This test do come clinic . - Urine Collection : Urine also collect keep research future . You ask pee cup . - Medical Information : We ask share medical information study researcher . Your medical information contain personal identification information , like name address . Optional : • Induced Sputum Collection : If say `` yes '' collect sputum sample , ask breathe salt water solution help cough sputum . If breathe salt water solution cough sputum last study visit , ask cough mucus cup</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Inclusion Criteria Core Study : 1 . Male female ≥ 6 year age Visit 1. : 2 . Must clinical diagnosis cystic fibrosis follow CFTR mutation : 1 . For Cohort 1 ( Closed enrollment June 30 , 2012 ) : G551D least 1 allele Any known unknown mutation allow second allele . 2 . For Cohort 2 : R117H least 1 allele Any known unknown mutation second allele except G551D 3 . For Cohort 3 : A NonG551D gate mutation one allele : ( G178R , S549N , S549R , G551S , G970R , G1244E , S1251N , S1255P , G1349D ) Any know unknown mutation second allele except G551D OR R117H 3 . Enrolled Cystic Fibrosis Foundation Patient Registry ( exception Canadian sit ) . ( Patients may enroll Registry Visit 1 previously enrol . ) 4 . Clinically stable significant change health status within 14 day prior Visit 1 . 5 . Written informed consent ( assent applicable ) obtain subject subject 's legal representative . Exclusion Criteria Core Study 1 . Participation VX770105 , VX770106 , VX770108 , VX770110 , VX770111 , VX770112 , VX770113 study , VX770 Extended Access Program use ivacaftor within 6 month prior Visit 1 . 2 . Any upper low respiratory symptom require treatment oral , inhaled IV antibiotic within 2 week prior Visit 1 . 3 . History solid organ transplantation . 4 . Presence condition abnormality opinion investigator would compromise safety patient quality data .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>G551D</keyword>
	<keyword>G551D Mutation</keyword>
</DOC>